Unknown

Dataset Information

0

Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours.


ABSTRACT: Central nervous system (CNS) tumours comprise 25% of the paediatric cancer diagnoses and are the leading cause of cancer-related death in children. Current treatments for paediatric CNS tumours are far from optimal and fail for those that relapsed or are refractory to treatment. Besides, long-term sequelae in the developing brain make it mandatory to find new innovative approaches. Chimeric antigen receptor T cell (CAR T) therapy has increased survival in patients with B-cell malignancies, but the intrinsic biological characteristics of CNS tumours hamper their success. The location, heterogeneous antigen expression, limited infiltration of T cells into the tumour, the selective trafficking provided by the blood-brain barrier, and the immunosuppressive tumour microenvironment have emerged as the main hurdles that need to be overcome for the success of CAR T cell therapy. In this review, we will focus mainly on the characteristics of the deadliest high-grade CNS paediatric tumours (medulloblastoma, ependymoma, and high-grade gliomas) and the potential of CAR T cell therapy to increase survival and patients' quality of life.

PROVIDER: S-EPMC8616287 | BioStudies |

REPOSITORIES: biostudies

Similar Datasets

| S-EPMC8263540 | BioStudies
| S-EPMC8000899 | BioStudies
| S-EPMC2567087 | BioStudies
| S-EPMC9242779 | BioStudies
| S-EPMC8057949 | BioStudies
| S-SCDT-EMBOJ-2019-103637 | BioStudies
| S-EPMC6960448 | BioStudies
| S-EPMC7220953 | BioStudies
| E-GEOD-73801 | BioStudies
2016-02-25 | E-GEOD-73801 | ArrayExpress